BioSpace News Archive

TreeFrog Therapeutics, a pure player in iPSC-derived cell therapies, announces the appointment of 2 senior executives and 2 independent board members.

As a global specialized Contract Research Organization providing high-quality protein analytical services to support research, manufacturing and clinical development of native and recombinant proteins, Creative BioMart recently released Intracellular Cytokine Detection and Activity Assay to help explore new frontiers in biological science.

Mako Medical is lowering pharmacy costs with a new mobile app aimed at pricing transparency and access to lower-cost meds. This new model uses cost-plus pricing — not retail rates.

Panthera, the newly launched independent clinical trial site management organisation, has opened its first site in Preston in the UK with a second site in North Manchester to open in March.

New physicians bring clinical expertise in pediatrics and women with epilepsy

Linshom announced U.S. Food and Drug Administration 510 clearance of the company’s first product, a small, non-invasive respiratory monitor that addresses the growing need for continuous respiratory monitoring for patients susceptible to respiratory depression and compromise.

Vectura Group plc announces a key appointment to support innovation, customer focus and growth as the company continues with its strategic development as a leading inhalation specialist in the pharmaceutical services space.

When used by adults every four days, ESPEROCT® can help reduce the frequency of bleeding with less frequent dosing

BrainStorm Cell Therapeutics, Inc. announced that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and full year ended December 31, 2019, and provide a corporate update, at 8:00 a.m., Eastern Time, on Tuesday, February 18, 2020.

Eli Lilly and Company announced that the analysis performed by Washington University School of Medicine in the Dominantly Inherited Alzheimer Network Trials Unit Study showed that solanezumab did not meet the primary endpoint.